101 related articles for article (PubMed ID: 23958516)
1. Design, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists.
Hasui T; Ohra T; Ohyabu N; Asano K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
Bioorg Med Chem; 2013 Oct; 21(19):5983-94. PubMed ID: 23958516
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
Hasui T; Ohyabu N; Ohra T; Fuji K; Sugimoto T; Fujimoto J; Asano K; Oosawa M; Shiotani S; Nishigaki N; Kusumoto K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
Bioorg Med Chem; 2014 Oct; 22(19):5428-45. PubMed ID: 25187277
[TBL] [Abstract][Full Text] [Related]
3. Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.
Hasui T; Matsunaga N; Ora T; Ohyabu N; Nishigaki N; Imura Y; Igata Y; Matsui H; Motoyaji T; Tanaka T; Habuka N; Sogabe S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
J Med Chem; 2011 Dec; 54(24):8616-31. PubMed ID: 22074142
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity.
Nordqvist A; O'Mahony G; Fridén-Saxin M; Fredenwall M; Hogner A; Granberg KL; Aagaard A; Bäckström S; Gunnarsson A; Kaminski T; Xue Y; Dellsén A; Hansson E; Hansson P; Ivarsson I; Karlsson U; Bamberg K; Hermansson M; Georgsson J; Lindmark B; Edman K
ChemMedChem; 2017 Jan; 12(1):50-65. PubMed ID: 27897427
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists.
Futatsugi K; Piotrowski DW; Casimiro-Garcia A; Robinson S; Sammons M; Loria PM; Banker ME; Petersen DN; Schmidt NJ
Bioorg Med Chem Lett; 2013 Dec; 23(23):6239-42. PubMed ID: 24157365
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.
Cox JM; Chu HD; Yang C; Shen HC; Wu Z; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
Bioorg Med Chem Lett; 2014 Apr; 24(7):1681-4. PubMed ID: 24630411
[TBL] [Abstract][Full Text] [Related]
7. Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.
Casimiro-Garcia A; Piotrowski DW; Ambler C; Arhancet GB; Banker ME; Banks T; Boustany-Kari CM; Cai C; Chen X; Eudy R; Hepworth D; Hulford CA; Jennings SM; Loria PM; Meyers MJ; Petersen DN; Raheja NK; Sammons M; She L; Song K; Vrieze D; Wei L
J Med Chem; 2014 May; 57(10):4273-88. PubMed ID: 24738581
[TBL] [Abstract][Full Text] [Related]
8. Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.
Lotesta SD; Marcus AP; Zheng Y; Leftheris K; Noto PB; Meng S; Kandpal G; Chen G; Zhou J; McKeever B; Bukhtiyarov Y; Zhao Y; Lala DS; Singh SB; McGeehan GM
Bioorg Med Chem; 2016 Mar; 24(6):1384-91. PubMed ID: 26897089
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of sterically encumbered 11β-aminoprogesterone derivatives and evaluation as 11β-hydroxysteroid dehydrogenase inhibitors and mineralocorticoid receptor antagonists.
Pandya K; Dietrich D; Seibert J; Vederas JC; Odermatt A
Bioorg Med Chem; 2013 Nov; 21(21):6274-81. PubMed ID: 24074876
[TBL] [Abstract][Full Text] [Related]
10. Towards selectively modulating mineralocorticoid receptor function: lessons from other systems.
Baxter JD; Funder JW; Apriletti JW; Webb P
Mol Cell Endocrinol; 2004 Mar; 217(1-2):151-65. PubMed ID: 15134814
[TBL] [Abstract][Full Text] [Related]
11. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
Rogerson FM; Yao Y; Smith BJ; Fuller PJ
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912
[TBL] [Abstract][Full Text] [Related]
12. SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.
Nariai T; Fujita K; Mori M; Katayama S; Hori S; Matsui K
J Pharmacol Sci; 2011; 115(3):346-53. PubMed ID: 21358118
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
Yang C; Shen HC; Wu Z; Chu HD; Cox JM; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
Bioorg Med Chem Lett; 2013 Aug; 23(15):4388-92. PubMed ID: 23777778
[TBL] [Abstract][Full Text] [Related]
14. Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.
Martín-Martínez M; Pérez-Gordillo FL; Álvarez de la Rosa D; Rodríguez Y; Gerona-Navarro G; González-Muñiz R; Zhou MM
J Med Chem; 2017 Apr; 60(7):2629-2650. PubMed ID: 28051871
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).
Takahashi M; Ubukata O; Homma T; Asoh Y; Honzumi M; Hayashi N; Saito K; Tsuruoka H; Aoki K; Hanzawa H
FEBS Lett; 2020 May; 594(10):1615-1623. PubMed ID: 31991486
[TBL] [Abstract][Full Text] [Related]
16. Substituted phenyl as a steroid A-ring mimetic: providing agonist activity to a class of arylsulfonamide nonsteroidal glucocorticoid ligands.
DiSalvo D; Kuzmich D; Bentzien J; Regan J; Kukulka A; Fadra-Khan T; Nelson R; Harcken C; Thomson D; Nabozny G
Bioorg Med Chem Lett; 2013 Dec; 23(24):6645-9. PubMed ID: 24239189
[TBL] [Abstract][Full Text] [Related]
17. Aldosterone antagonists. 2. Synthesis and biological activities of 11,12-dehydropregnane derivatives.
Kamata S; Matsui T; Haga N; Nakamura M; Odaguchi K; Itoh T; Shimizu T; Suzuki T; Ishibashi M; Yamada F
J Med Chem; 1987 Sep; 30(9):1647-58. PubMed ID: 3040999
[TBL] [Abstract][Full Text] [Related]
18. Novel non-steroidal/non-anilide type androgen antagonists: discovery of 4-substituted pyrrole-2-carboxamides as a new scaffold for androgen receptor ligands.
Wakabayashi K; Miyachi H; Hashimoto Y; Tanatani A
Bioorg Med Chem; 2005 Apr; 13(8):2837-46. PubMed ID: 15781394
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.
Ogawa AK; Bunte EV; Mal R; Lan P; Sun Z; Crespo A; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Jochnowitz N; Ma X; Pan Y; Brown P; Zamlynny B; Bateman T; Leung D; Xu L; Tong X; Liu K; Crook M; Sinclair P
Bioorg Med Chem Lett; 2016 Jun; 26(12):2866-2869. PubMed ID: 27161805
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid Receptor Antagonists.
Nordqvist A; Granberg KL
Vitam Horm; 2019; 109():151-188. PubMed ID: 30678854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
